TESARO (NASDAQ: TSRO) reported Q1 EPS of ($2.98), $0.28 worse than the analyst estimate of ($2.70). Revenue for the quarter came in at $50.2 million versus the consensus estimate of $56.93 million.

• ZEJULA Q1 net sales totaled $49 million
• Enrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial
• TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer data accepted for oral presentations at ASCO
• Initial data from two TSR-042 (anti-PD-1) GARNET expansion cohorts presented at AACR; regulatory submission for MSI-high tumors planned in 2019

For earnings history and earnings-related data on TESARO (TSRO) click here.